文献速递膀胱癌与上尿路尿路上皮癌

DaBlaCa-13研究:短期强化化疗消融对比标准辅助膀胱灌注治疗非肌层浸润性膀胱癌的随机对照试验

The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
PubMed 文献 · Eur Urol · 2020-07-28

这项随机对照试验纳入120例复发性Ta期低级别或高级别膀胱肿瘤患者,比较短期强化丝裂霉素C化疗消融(59例)与经尿道膀胱肿瘤电切术加六周辅助灌注(61例)。干预组完全肿瘤反应率为57%,且不良事件报告少于对照组;因不良事件停止灌注治疗者两组各2例。短期强化化疗消融可使超过半数患者避免手术,但缺乏长期随访。

要点

  • 短期强化丝裂霉素C化疗消融完全肿瘤反应率为57%
  • 化疗消融组不良事件报告少于标准辅助灌注组
  • 两组各2例因不良事件停止灌注治疗

核心结论

  • 短期强化化疗消融获得57%的肿瘤反应率,仅半数接受该治疗者需行TURBT,且临床显著副作用更少。
  • 因样本量小,对Ta高级别肿瘤需进一步研究。

研究设计与样本

  • 随机对照试验,2018年1月至2019年6月在丹麦两个泌尿外科开展,共纳入120例复发性Ta期低级别或高级别膀胱肿瘤患者。
  • 干预组59例接受丝裂霉素C(40 mg/40 ml)膀胱灌注每周3次共2周;对照组61例接受TURBT及术后六周每周辅助灌注。

主要发现

  • 干预组33例(57%)在4周后软性膀胱镜检查显示完全肿瘤反应。
  • 干预组报告的不良事件少于对照组。
  • 两组各有2例因不良事件停止灌注治疗。

关键数值与推荐

  • 干预组肿瘤反应于4周后经软性膀胱镜评估。
  • 不良事件采用美国国家癌症研究所常见不良事件术语标准前瞻性登记。
  • 组间比较采用χ2检验或Fisher精确检验。

临床怎么用

  • 对复发性Ta期低级别或高级别NMIBC,短期强化丝裂霉素C化疗消融可使57%患者避免TURBT且副作用较少。
  • 因缺乏长期随访及Ta高级别肿瘤样本量小,需进一步研究后再推广。

局限性

  • 当前缺乏长期随访。
  • 因样本量小,对Ta高级别肿瘤需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Instillation therapy for non-muscle-invasive bladder cancer (NMIBC) reduces recurrences but is associated with side effects. Preoperative instillation of chemotherapy could potentially be associated with fewer side effects compared with adjuvant instillations and in some patients make tumour resection (transurethral resection of the bladder tumour [TURBT]) superfluous. OBJECTIVE: To investigate tumour response and adverse events related to short-term, intensive chemoresection with mitomycin C compared with adjuvant instillations in patients with recurrent NMIBC. DESIGN, SETTING, AND PARTICIPANTS: A randomised, controlled trial was conducted in two urological departments in Denmark from January 2018 to June 2019. In total, 120 participants with a history of Ta bladder tumours, low grade or high grade, were included upon recurrence. INTERVENTION: Intravesical mitomycin C (40 mg/40 ml) three times a week for 2 wk in the intervention group (59 patients) was compared with TURBT and six weekly adjuvant instillations in the control group (61 patients). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Tumour response was evaluated in the intervention group by flexible cystoscopy after 4 wk. Side effects were prospectively registered in both groups using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Groups were compared using χ2 or Fisher's exact test. RESULTS AND LIMITATIONS: Complete tumour response was seen in 33 participants (57%) in the intervention group. Fewer adverse events were reported in the intervention group than in the control group. Two patients in each group ceased instillation treatment due to adverse events. The main limitation is the current lack of long-term follow-up. CONCLUSIONS: Short-term, intensive chemoresection yields a tumour response of 57%. Hence, only half of those treated with chemoresection needed TURBT. The treatment was furthermore associated with fewer clinically significant side effects. Owing to small numbers, further investigations on Ta high-grade tumours are needed. PATIENT SUMMARY: We compared a nonsurgical treatment with standard treatment in patients with superficial bladder tumours. We found it to be safe and able to avoid surgery in more than half of the patients.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lindgren MS, Bue P, Azawi N, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial. Eur Urol. 2020. PMID: 32736928. doi:10.1016/j.eururo.2020.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。